The global push toward precision medicine is reshaping the underlying framework of the Alpha Synuclein Market, steering it away from blanket therapeutic models toward highly stratified patient-care approaches. The discovery that distinct structural strains of alpha-synuclein polymorphs correlate with specific clinical phenotypes (such as the differences between Parkinson's and MSA) has...